Postdoc 'Novel immunotherapeutic targeting of B cell malignancies and effects on neutrophils'

Updated: over 1 year ago
Job Type: Temporary
Deadline: 07 Sep 2022

In this project, we will study novel CD37 antibodies (''hexabodies'') in their cytotoxic capacity in human lymphomas. Secondly, we aim to identify the underlying molecular mechanism by investigating downstream signaling and CD37 organization at the cell surface of lymphomas and primary immune cells (neutrophils) using advanced microscopy techniques. Will you join our team?

Tetraspanins belong to the transmembrane-4-superfamily that consists of small (20-50 kDa) transmembrane proteins that are abundantly expressed at the cell surface. We discovered that the B cell-specific tetraspanin CD37 is a novel tumor suppressor in lymphoma (de Winde et al. J. Clin.Invest. 2016, Elfrink et al. Blood 2019, Peeters et al. In Press 2022).

Targeting CD37 is currently under clinical investigation in patients with aggressive lymphomas (de Winde et al. Trends in Cancer 2017, Oostindie et al., Blood Cancer J. 2020). This project is supported through the ERC (Consolidator Grant) and in collaboration with Genmab.



Similar Positions